

# Breakthrough T1D Network for Canada



Canada has a narrow window to lead in regenerative medicine.  
Type 1 diabetes (T1D) is where Canada is ready now.

## Why now

Cell and gene therapies are moving into real-world clinical use.

Countries that act now are anchoring trials, talent, and investment.

Canada risks losing discoveries to other jurisdictions without coordination.

## Why type 1 diabetes



### 1. Clinically Ready

Multiple cell-based therapies already in or near trials — including in Canada.



### 2. Canadian Strength

Canada has performed more insulin-producing cell transplants than any other country.



### 3. Clear Results

Outcomes like insulin independence are measurable and fast.



### 4. Transferable Skills

The same systems apply to cancer, rare disease, and organ repair.

T1D is among the diseases closest to a curative breakthrough in regenerative medicine.



## The problem

Canada funds excellent research, but lacks a coordinated way to move discoveries through trials, manufacturing, regulation, and delivery. As a result, trials, talent, and commercialization often leave the country. Valuable science becomes economic value elsewhere.

# What the Breakthrough T1D Network for Canada (BTNC) is:



- A federally anchored, public-private partnership
- Not a new building or institute
- A coordinated, pan-Canadian way to actively manage regenerative medicine trials and translation



## What BTNC does:

### 1. Select

Focus national resources on the most promising T1D therapies.

### 3. Deliver

Support shared protocols, workforce training, and trial execution.

### 2. Coordinate

Align trials across sites, timelines, and standards.

### 4. Commercialize

Partner with Canadian organizations to keep value in Canada.

## What BTNC enables:



### STATUS QUO

- Fragmented trials
- Slower progress
- Less success
- Value leaks abroad

### With BTNC

- Coordinated trials
- Faster results
- Higher success rate
- Value stays in Canada



## Impact in the first five years:

# 2x

the number of T1D cure therapies trialed in Canada

# 10+

academic discoveries supported toward commercialization

# 120+

highly skilled jobs created

## Investment Model



- Every federal research dollar is matched at least **1:1**.

## Economic + Health Return

- Health R&D delivers strong GDP returns.
- A **\$100M** investment could generate ~**\$575M** in economic value.
- Earlier cures could reduce billions in long-term healthcare costs.

## Why Breakthrough T1D

- **50+** years funding and managing T1D research
- **\$3B+** invested globally [since 1970]
- **20+** Canadian T1D trials supported jointly with federal funds [since 2009]
- Proven governance, peer review, and accountability

# Why federal leadership matters

Only the federal government can catalyze a coordinated, pan-Canadian effort at this scale. BTNC offers a disciplined, low risk way to turn Canadian science into Canadian health and economic gains.

**Canada discovered insulin.**

Regenerative medicine for T1D is our chance to lead again — and keep the benefits here.

